Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Courtney D DiNardo & Jorge E Cortes. (2015) New treatment for acute myelogenous leukemia. Expert Opinion on Pharmacotherapy 16:1, pages 95-106.
Read now
Read now
Niamh Keane, Ciara Freeman, Ronan Swords & Francis J Giles. (2013) Elacytarabine: lipid vector technology under investigation in acute myeloid leukemia. Expert Review of Hematology 6:1, pages 9-24.
Read now
Read now
RichardJ. Honeywell, Elisa Giovannetti & G.J. Peters. (2011) Determination of the Phosphorylated Metabolites of Gemcitabine and of Difluorodeoxyuridine by LCMSMS. Nucleosides, Nucleotides & Nucleic Acids 30:12, pages 1203-1213.
Read now
Read now
Silke Henrich, Swetlana Mactier, Giles Best, StephenP. Mulligan, Ben Crossett & Richard
Ian Christopherson. (2011) Fludarabine Nucleoside Modulates Nuclear “Survival and Death” Proteins in Resistant Chronic Lymphocytic Leukemia Cells. Nucleosides, Nucleotides & Nucleic Acids 30:12, pages 1181-1189.
Read now
Read now
Articles from other publishers (13)
Mingyang Zhang, Chunlin Guo, Yifan Miao, Zhonggui He, Chutong Tian & Jin Sun. (2022) Incorporating a Lipophilic Disulfide-Bridged Linoleic Prodrug into a Self-Microemulsifying Drug Delivery System to Facilitate Oral Absorption of Paclitaxel. Molecular Pharmaceutics 20:1, pages 461-472.
Crossref
Crossref
Galal H. Elgemeie & Reham A. Mohamed-Ezzat. 2022. New Strategies Targeting Cancer Metabolism. New Strategies Targeting Cancer Metabolism
107
142
.
Nadia Fattahi, Mohammad-Ali Shahbazi, Aziz Maleki, Mehrdad Hamidi, Ali Ramazani & Hélder A. Santos. (2020) Emerging insights on drug delivery by fatty acid mediated synthesis of lipophilic prodrugs as novel nanomedicines. Journal of Controlled Release 326, pages 556-598.
Crossref
Crossref
Peter M. Alexander, Gregory L. Kucera, Kristin M. Pladna & Timothy S. Pardee. (2020) The Novel Phospholipid Mimetic KPC34 Is Highly Active Against Acute Myeloid Leukemia with Activated Protein Kinase C. Translational Oncology 13:7, pages 100780.
Crossref
Crossref
Yanyan Chu, Zhenhua Tian, Yingwei Hou & Wenbao Li. (2018) Study on the Preparation and Antileukemic Activity of New Lipophilic 1-β-D-arabinofuranosylcytosine Derivatives. Journal of Ocean University of China 17:2, pages 385-391.
Crossref
Crossref
Bingjun Sun, Cong Luo, Weiping Cui, Jin Sun & Zhonggui He. (2017) Chemotherapy agent-unsaturated fatty acid prodrugs and prodrug-nanoplatforms for cancer chemotherapy. Journal of Controlled Release 264, pages 145-159.
Crossref
Crossref
Jadd Shelton, Xiao Lu, Joseph A. Hollenbaugh, Jong Hyun Cho, Franck Amblard & Raymond F. Schinazi. (2016) Metabolism, Biochemical Actions, and Chemical Synthesis of Anticancer Nucleosides, Nucleotides, and Base Analogs. Chemical Reviews 116:23, pages 14379-14455.
Crossref
Crossref
Aditya G. Kohli, Paul H. Kierstead, Vincent J. Venditto, Colin L. Walsh & Francis C. Szoka. (2014) Designer lipids for drug delivery: From heads to tails. Journal of Controlled Release 190, pages 274-287.
Crossref
Crossref
Godefridus J. Peters, Kees Smid, Leonardo Vecchi, Ietje Kathmann, Dzjemma Sarkisjan, Richard J. Honeywell, Nienke Losekoot, Osnat Ohne, Aric Orbach, Eran Blaugrund, Lak Shin Jeong, Young Bok Lee, Chang-Ho Ahn & Deog Joong Kim. (2013) Metabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360). Investigational New Drugs 31:6, pages 1444-1457.
Crossref
Crossref
Courtney D DiNardo, Susan O’Brien, Varsha V Gandhi & Farhad Ravandi. (2013) Elacytarabine (CP-4055) in the treatment of acute myeloid leukemia. Future Oncology 9:8, pages 1073-1082.
Crossref
Crossref
Auke D. Adema, Kees Smid, Nienke Losekoot, Richard J. Honeywell, Henk M. Verheul, Finn Myhren, Marit L. Sandvold & Godefridus J. Peters. (2011) Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126. Investigational New Drugs 30:5, pages 1908-1916.
Crossref
Crossref
Susan O'Brien, David A. Rizzieri, Norbert Vey, Farhad Ravandi, Utz O. Krug, Mikkael A. Sekeres, Mike Dennis, Adriano Venditti, Donald A. Berry, Tove Flem Jacobsen, Karin Staudacher, Trygve Bergeland & Francis J. Giles. (2012) Elacytarabine has single‐agent activity in patients
with advanced acute myeloid leukaemia. British Journal of Haematology 158:5, pages 581-588.
Crossref
Crossref
Francis Giles, David Rizzieri, Farhad Ravandi, Ronan Swords, Tove Flem Jacobsen & Susan O’Brien. (2012) Elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia. Leukemia Research 36:4, pages e71-e73.
Crossref
Crossref